Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPB postbiotic
- Development stage
- Preclinical
- Lead developer
- NutriTechLab
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
iPB postbiotic is an innovative postbiotic product developed through the sequential fermentation of *Lacticaseibacillus rhamnosus* GG and *Lacticaseibacillus paracasei* NPB-01 (DSM 34367). It is designed to enhance epithelial gut barrier integrity, modulate innate immunity, and exert antitumor activities, particularly against breast cancer. In preclinical models, iPB has been shown to reduce cell viability and migration across various breast cancer subtypes (including MCF7, MDA-MB-231, and SKBR3) while increasing apoptosis and HLA class I surface expression, which potentially enhances immunogenicity. Additionally, it upregulates tight junction proteins (such as occludin and zonula occludens 1) and mucin-2 (MUC2) expression, and stimulates the production of human beta-defensin 2 (HBD-2) in human enterocytes.
- Other names
- innovative postbiotic productsequential postbiotic
02
Targets
FFAR2FFAR3 (Free fatty acid receptor 3)HCAR2 (Hydroxycarboxylic acid receptor 2)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on iPB postbiotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPB postbiotic.